Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Lilly forecasts weak sales of weight-loss drug in fourth quarter
Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
FiercePharma3d
JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market
Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...
JD Supra2d
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed
Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...
FiercePharma19h
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
Baltimore City school system sues drug companies over allegedly inflated price of insulin
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
Morningstar2d
Eli Lilly and Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Dayton Daily News3d
Stock market today: Wall Street mostly rises after encouraging inflation data despite Lilly's drag
Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check.